Two of the PTMs were treated with anti-human CD8 monoclonal antibody (MAb) cM-T807 subcutaneously on day 1 (10 mg/kg of body weight), and intravenously on days 4, and 7 (5 mg/kg of body weight) post-infection. This evidence concerns the gene CD8A and infection.